JP2024024114A5 - - Google Patents

Download PDF

Info

Publication number
JP2024024114A5
JP2024024114A5 JP2024002528A JP2024002528A JP2024024114A5 JP 2024024114 A5 JP2024024114 A5 JP 2024024114A5 JP 2024002528 A JP2024002528 A JP 2024002528A JP 2024002528 A JP2024002528 A JP 2024002528A JP 2024024114 A5 JP2024024114 A5 JP 2024024114A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024002528A
Other languages
English (en)
Japanese (ja)
Other versions
JP7688175B2 (ja
JP2024024114A (ja
Filing date
Publication date
Priority claimed from JP2021559435A external-priority patent/JP7511576B2/ja
Application filed filed Critical
Publication of JP2024024114A publication Critical patent/JP2024024114A/ja
Publication of JP2024024114A5 publication Critical patent/JP2024024114A5/ja
Priority to JP2025085725A priority Critical patent/JP2025113406A/ja
Application granted granted Critical
Publication of JP7688175B2 publication Critical patent/JP7688175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024002528A 2019-04-10 2024-01-11 Ｒｅｔを結合するヒト抗体およびその使用方法 Active JP7688175B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025085725A JP2025113406A (ja) 2019-04-10 2025-05-22 Ｒｅｔを結合するヒト抗体およびその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962832218P 2019-04-10 2019-04-10
US62/832,218 2019-04-10
JP2021559435A JP7511576B2 (ja) 2019-04-10 2020-04-09 Ｒｅｔを結合するヒト抗体およびその使用方法
PCT/US2020/027554 WO2020210551A1 (en) 2019-04-10 2020-04-09 Human antibodies that bind ret and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021559435A Division JP7511576B2 (ja) 2019-04-10 2020-04-09 Ｒｅｔを結合するヒト抗体およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025085725A Division JP2025113406A (ja) 2019-04-10 2025-05-22 Ｒｅｔを結合するヒト抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2024024114A JP2024024114A (ja) 2024-02-21
JP2024024114A5 true JP2024024114A5 (https=) 2024-04-02
JP7688175B2 JP7688175B2 (ja) 2025-06-03

Family

ID=70554175

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021559435A Active JP7511576B2 (ja) 2019-04-10 2020-04-09 Ｒｅｔを結合するヒト抗体およびその使用方法
JP2024002528A Active JP7688175B2 (ja) 2019-04-10 2024-01-11 Ｒｅｔを結合するヒト抗体およびその使用方法
JP2025085725A Pending JP2025113406A (ja) 2019-04-10 2025-05-22 Ｒｅｔを結合するヒト抗体およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021559435A Active JP7511576B2 (ja) 2019-04-10 2020-04-09 Ｒｅｔを結合するヒト抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025085725A Pending JP2025113406A (ja) 2019-04-10 2025-05-22 Ｒｅｔを結合するヒト抗体およびその使用方法

Country Status (11)

Country Link
US (1) US20220185900A1 (https=)
EP (1) EP3953390A1 (https=)
JP (3) JP7511576B2 (https=)
KR (1) KR20210150509A (https=)
CN (1) CN113993898B (https=)
AU (1) AU2020270966B2 (https=)
CA (1) CA3134258A1 (https=)
IL (1) IL287067A (https=)
MA (1) MA55615A (https=)
MX (1) MX2021012335A (https=)
WO (1) WO2020210551A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503508A (ja) 2021-01-15 2024-01-25 シージェン インコーポレイテッド 免疫調節性抗体－薬物コンジュゲート
BR112023015561A2 (pt) 2021-02-03 2023-11-14 Univ Minnesota Compostos imunoestimuiladores e conjugados
US20250154236A1 (en) * 2022-01-31 2025-05-15 Glaxosmithkline Intellectual Property (No. 3) Limited Prevention and treatment of headaches
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
JP2025525904A (ja) 2022-08-03 2025-08-07 シージェン インコーポレイテッド 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
TW202541841A (zh) * 2023-12-20 2025-11-01 美商黛安瑟斯醫療運營公司 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20090202562A1 (en) * 2005-06-17 2009-08-13 Biogen Idec Ma Inc. Anti-gfralpha3 antibodies
EP1941909A4 (en) * 2005-10-24 2012-05-23 Takeda Pharmaceutical PREVENTIVE MEASURES / REMEDIES FOR CANCER
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
PT2387583T (pt) 2009-01-14 2018-12-24 Ablynx Nv Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
GB201512215D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
KR101859576B1 (ko) * 2016-06-30 2018-05-18 가톨릭대학교 산학협력단 Kif5b-ret 융합 단백질을 특이적으로 검출하는 항체 및 이의 용도
AU2018336785B2 (en) * 2017-09-20 2022-07-14 Regeneron Pharmaceuticals, Inc. Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden

Similar Documents

Publication Publication Date Title
JP2024024114A5 (https=)
JP2024020298A5 (https=)
JP2022177090A5 (https=)
JP2024109678A5 (https=)
JP2024038003A5 (https=)
JP2021521843A5 (https=)
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
JP2022533538A5 (https=)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2023093753A5 (https=)
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2025067915A5 (https=)
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2020522280A5 (https=)
JP2020514277A5 (https=)
JP2020522281A5 (https=)
JP2024540148A5 (https=)
JP2020521504A (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
JP2023510844A5 (https=)
JP2021512652A5 (https=)
CN111712521A (zh) Cd38蛋白抗体及其应用
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途